Dismantling relapsed/refractory mantle cell lymphoma Review
| Authors: | Ryan, C. E.; Kumar, A. |
| Review Title: | Dismantling relapsed/refractory mantle cell lymphoma |
| Abstract: | Despite recent therapeutic advancements in the general field of non-Hodgkin lymphoma, effective treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL) remains a challenge. The development of Bruton tyrosine kinase (BTK) inhibitors has revolutionized the field and these agents are now the mainstay of R/R MCL management. However, BTK inhibitors are not curative, and as they are increasingly being incorporated into frontline regimens, the shifting treatment landscape for R/R disease presents new challenges. Here we review data for commonly employed treatment strategies including BTK inhibitors, the BCL2-inhibitor venetoclax, lenalidomide-based regimens, and chimeric antigen receptor T-cell therapy. We additionally review data for promising novel agents including antibody-drug conjugates and bispecific antibodies before highlighting some emerging targeted agents that continue to bring promise for improved outcomes in R/R MCL. © 2024 |
| Keywords: | lenalidomide; review; side effect; antineoplastic agents; antineoplastic agent; mantle cell lymphoma; protein kinase inhibitor; antineoplastic combined chemotherapy protocols; drug effect; drug resistance; drug resistance, neoplasm; protein kinase inhibitors; drug combination; phase 1 clinical trial; disease management; drug therapy; adverse drug reaction; therapy; adoptive immunotherapy; immunotherapy, adoptive; pharmacokinetics; pharmacology; lymphoma, mantle-cell; non-hodgkin lymphoma; targeted therapies; molecularly targeted therapy; molecular targeted therapy; procedures; novel agents; bruton tyrosine kinase; bispecific antibody; refractory disease; humans; human; agammaglobulinaemia tyrosine kinase; venetoclax; antibody drug conjugate; chimeric antigen receptor t-cell immunotherapy; btk protein, human; relapsed/refractory disease |
| Journal Title: | Blood Reviews |
| Volume: | 67 |
| ISSN: | 0268-960X |
| Publisher: | Churchill Livingstone |
| Date Published: | 2024-09-01 |
| Start Page: | 101221 |
| Language: | English |
| DOI: | 10.1016/j.blre.2024.101221 |
| PUBMED: | 38906740 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
